The Alteration of Circulating Lymphocyte Subsets During Tacrolimus Therapy in Neuromyelitis Optica Spectrum Disorder and Its Correlation With Clinical Outcomes

ObjectivesWe aimed to explore the alteration of circulating lymphocyte subsets before and after tacrolimus (TAC) therapy in neuromyelitis optica spectrum disorder (NMOSD) and its correlation with clinical outcomes. MethodsAnti-aquaporin-4 antibody (AQP4-ab)-positive patients with NMOSD treated with TAC were followed and clinically evaluated at 0, 3, 6, and 12 months after initiation of TAC. Flow cytometry was employed to detect the proportion of various whole blood lymphocyte subsets at every time point. Correlation analysis was further performed to explore the association between annualized relapse rate (ARR), the Expanded Disability Status Scale (EDSS) score, and the proportion of circulating lymphocyte subsets before and after TAC therapy. ResultsA total of 13 eligible patients with NMOSD were included. The proportion of CD19(+)CD24(hi)CD38(hi)/CD19(+) and CD19(+)CD5(+)CD1d(hi)/CD19(+) lymphocyte subsets increased significantly after TAC therapy (p = 0.010 and p < 0.001). The proportion of CD19(+)BAFFR(+), CD19(+)IFN-gamma(+), and CD19(+)IL-10(+) subsets decreased significantly after TAC therapy (p = 0.015, 0.018, and 0.042, respectively). There was a negative correlation between CD4(+)CD25(hi) subset and EDSS score (p = 0.016, r = -0.652). ConclusionPossibly through increasing regulatory B and suppressing BAFFR(+) B and interferon (IFN)-gamma(+) B subsets, TAC could decrease relapse. EDSS score may be correlated with some lymphocyte subsets after TAC therapy.

Automated summary

This study aimed to investigate the changes in circulating lymphocyte subsets before and after tacrolimus (TAC) therapy in patients with neuromyelitis optica spectrum disorder (NMOSD), and their correlation with clinical outcomes. The results showed that TAC therapy significantly altered the proportions of certain lymphocyte subsets, and there was a correlation between lymphocyte subsets and clinical scores.